LSV Asset Management Has $6.61 Million Stock Position in Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX)

LSV Asset Management decreased its holdings in shares of Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) by 23.8% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 1,089,300 shares of the company’s stock after selling 340,000 shares during the quarter. LSV Asset Management owned 0.36% of Amneal Pharmaceuticals worth $6,612,000 at the end of the most recent quarter.

A number of other institutional investors have also added to or reduced their stakes in AMRX. Gladius Capital Management LP bought a new stake in shares of Amneal Pharmaceuticals in the 3rd quarter valued at about $39,000. Sherbrooke Park Advisers LLC bought a new stake in shares of Amneal Pharmaceuticals during the 3rd quarter valued at about $54,000. Aigen Investment Management LP acquired a new position in Amneal Pharmaceuticals in the third quarter valued at approximately $118,000. Public Employees Retirement System of Ohio bought a new stake in shares of Amneal Pharmaceuticals in the 3rd quarter valued at $160,000. Finally, EMC Capital Management boosted its stake in Amneal Pharmaceuticals by 886.7% during the third quarter. EMC Capital Management now owns 40,613 shares of the company’s stock worth $171,000 after acquiring an additional 36,497 shares in the last quarter. 31.82% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of research analysts recently weighed in on the company. Truist Financial reaffirmed a “buy” rating and set a $9.00 price target (up from $7.00) on shares of Amneal Pharmaceuticals in a research note on Monday. StockNews.com downgraded Amneal Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research note on Monday, March 4th. Piper Sandler increased their price target on Amneal Pharmaceuticals from $6.00 to $8.00 and gave the company an “overweight” rating in a research report on Thursday, March 21st. The Goldman Sachs Group raised their price target on shares of Amneal Pharmaceuticals from $6.25 to $8.00 and gave the company a “buy” rating in a research report on Monday. Finally, Barclays boosted their target price on Amneal Pharmaceuticals from $6.00 to $8.00 and gave the stock an “overweight” rating in a research note on Monday, January 29th. Five research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, Amneal Pharmaceuticals presently has a consensus rating of “Buy” and an average target price of $8.25.

Amneal Pharmaceuticals Stock Performance

Shares of AMRX opened at $6.59 on Thursday. The stock’s 50-day simple moving average is $5.79 and its 200 day simple moving average is $5.34. Amneal Pharmaceuticals, Inc. has a 52-week low of $1.74 and a 52-week high of $6.90. The stock has a market capitalization of $2.02 billion, a price-to-earnings ratio of -11.77 and a beta of 1.33. The company has a debt-to-equity ratio of 121.31, a quick ratio of 0.97 and a current ratio of 1.65.

Amneal Pharmaceuticals (NASDAQ:AMRX) last posted its quarterly earnings data on Friday, March 1st. The company reported $0.12 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.05 by $0.07. The company had revenue of $616.98 million during the quarter, compared to analyst estimates of $630.67 million. Amneal Pharmaceuticals had a positive return on equity of 234.06% and a negative net margin of 6.76%. Research analysts forecast that Amneal Pharmaceuticals, Inc. will post 0.5 EPS for the current fiscal year.

About Amneal Pharmaceuticals

Amneal Pharmaceuticals, Inc, together with its subsidiaries, develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products worldwide. The company operates through three segments: Generics, Specialty, and AvKARE. The Generics segment offers immediate and extended release oral solid, powder, liquid, sterile injectable, nasal spray, inhalation and respiratory, biosimilar, ophthalmic, film, transdermal patch, and topical products.